Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. today announced financial results for the second quarter of fiscal year (FY) 2010 ended October 31, 2009. Total revenue for the second quarter of FY 2010 increased 255% to $6,896,000, compared to $1,941,000 for the comparable prior year quarter.

10 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009

Mobile phone does not increase risk of brain tumour

A new study has found no increase in the incidence of brain tumours during the years immediately following the introduction of mobile phones in Nordic countries.

5 Dec 2009

Videos can help overcome communication barriers and influence patients' choices for medical care

Patients with terminal brain cancer who watched a brief video illustrating options for end-of-life care were significantly more likely to indicate a preference for comfort measures only than were patients who listened to a verbal description of treatment choices.

3 Dec 2009

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Duke University Medical Center researchers have figured out how stem cells in the malignant brain cancer glioma may be better able to resist radiation therapy. And using a drug to block a particular signaling pathway in these cancer stem cells, they were able to kill many more glioma cells with radiation in a laboratory experiment.

2 Dec 2009

Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial

Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for GBM.

2 Dec 2009

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.

2 Dec 2009

Development of novel virus can lead to new therapeutic strategy to combat cancer

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels.

2 Dec 2009

Varian Medical Systems to exhibit its full range of detectors at RSNA Annual Meeting in Chicago

Varian Medical Systems, Inc., a premier supplier of X-ray tubes and flat panel digital image detectors, will exhibit its full range of detectors at the RSNA Annual Meeting in Chicago, Ill. from November 29 - December 3, 2009. Varian will also be exhibiting X-ray tube technology for multiple modalities as well as specialized cancer treatment technologies.

27 Nov 2009

Faulty enzyme may contribute to malignant brain tumour formation

Around 70 per cent of people with a type of brain tumour - called a low-grade glioma - have a faulty version of an enzyme called IDH1. The mutation is also found in a significant proportion of patients with acute myeloid leukaemia.

25 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

23 Nov 2009

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

Long durations of exposure to formaldehyde used for embalming in the funeral industry were associated with an increased risk of death from myeloid leukemia, according to a new study published online November 20 in the Journal of the National Cancer Institute.

21 Nov 2009

EIN News launches "Mesothelioma News Today"

EIN News, an online leader in industry news monitoring and press syndication, has today added a new publication to its portfolio of health-related international news sites for industry professionals and analysts: Mesothelioma News Today (http://mesothelioma.einnews.com).

19 Nov 2009

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body.

18 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

NIH offers $1.6 million, three-year grant to Prism Clinical Imaging

Prism Clinical Imaging, Inc., in collaboration with investigators at The Medical College of Wisconsin in Milwaukee, has received a $1.6 million, three-year grant from the National Institutes of Health (NIH) to develop and clinically validate advanced medical imaging software that aids the diagnosis and treatment of patients with brain cancer.

16 Nov 2009

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

Bradmer Pharmaceuticals Inc. today announced its 2009 third quarter financial results.

12 Nov 2009

First evidence-based, multidisciplinary treatment guidelines for brain metastases patients to be published

Anthony Asher, MD, FACS, of Carolina Neurosurgery & Spine Associates in Charlotte, NC, has co-authored the first evidence-based, multidisciplinary treatment guidelines for brain metastases patients. These guidelines were recently presented at the Congress of Neurological Surgeons 2009 Annual Meeting in New Orleans, and were developed over the last year by a 20-member panel from various medical specialties.

11 Nov 2009

Brain Cancer News and Research

Further Reading

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

TMZ and small molecule combination appears to lower tumor resistance

Albert Einstein College of Medicine receives SU2C grant for cancer research

Mobile phone does not increase risk of brain tumour

Videos can help overcome communication barriers and influence patients' choices for medical care

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

Development of novel virus can lead to new therapeutic strategy to combat cancer

Varian Medical Systems to exhibit its full range of detectors at RSNA Annual Meeting in Chicago

Faulty enzyme may contribute to malignant brain tumour formation

Mutated IDH1 gene linked to the progression of gliomas

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

EIN News launches "Mesothelioma News Today"

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

NIH offers $1.6 million, three-year grant to Prism Clinical Imaging

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

First evidence-based, multidisciplinary treatment guidelines for brain metastases patients to be published

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News